Answers are grounded in this paper and cite their sources.
A treatment's time toxicity (measured using contact days) can decrease days spent at home (home days). We evaluated the minimum clinically important difference (MCID) and non-inferiority margin (NIM) of home days, and treatment acceptance when all additional survival time was spent in health care by surveying people with lived (patients, n = 42; informal care partners, n = 29) and professional (oncologists, n = 8) experience of advanced cancer. All 3 groups reported similar MCIDs and NIMs (6-month survival; median MCID range, 14-15; P = .79; median NIM range, 5-11; P = .14). Care partners (48%) and patients (21%) more often accepted 2-week survival gains without an increase in home days than oncologists (0%), P = .09. Caregivers reported altruism guided their responses, and clinicians' responses in stated-preference work may differ from revealed-preferences in the clinic. By empirically deriving MCID/NIM for home days and evaluating treatment acceptance, this work will aid trial design and decision studies using an endpoint of home days.
No takes yet. Share an insight, caveat, or question.
Gupta et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: